Eureka Therapeutics Appoints Dr. Reginald Seeto and William S. Solari III to Board of Directors
"Their guidance will be instrumental as we advance key clinical milestones and unlock the full potential of our pipeline," said Cheng Liu, Ph.D., Founder and CEO of Eureka Therapeutics.
Dr. Seeto is a global leader in biopharmaceuticals and diagnostics with expertise in corporate strategy, business development, and operations. He currently serves as President and CEO of Scipher Medicine. Previously, he was President and CEO of CareDx, Inc., guiding the company through a period of rapid growth. He served as Chief Operating Officer at Ardelyx, where he built international partnerships to support commercialization, and held senior leadership roles at AstraZeneca, where he completed over 100 biologics transactions and managed portfolio strategy for more than 150 assets. His earlier career includes McKinsey & Company, Boehringer Ingelheim, and Organon.
Mr. Solari brings over 30 years of legal and financial experience in corporate governance, mergers and acquisitions, and complex tax structuring. He was a partner at Jeffer Mangels Butler & Mitchell LLP before founding his own law practice, where he continues to advise clients across diverse industries.
'Reg and Bill bring exceptional leadership and strategic insight to our Board,' said Cheng Liu, Ph.D., Founder and CEO of Eureka Therapeutics. 'Their guidance will be instrumental as we advance key clinical milestones and unlock the full potential of our pipeline.'
ABOUT EUREKA THERAPEUTICS, INC.
Eureka's proprietary ARTEMIS ® CAR-T platform is designed to overcome key limitations of conventional CAR-T therapies by reducing toxicity to enable higher doses and repeat infusions, improving T-cell persistence for longer-lasting responses, and enhancing tumor infiltration to achieve more potent anti-tumor activity. Eureka's pipeline includes ET140203 (ARYA-2) for pediatric patients and ECT204 (ARYA-3) for adults, both in Phase I/II clinical trials for advanced liver cancer.
Eureka Therapeutics, Inc. is headquartered in the San Francisco Bay Area. For more information, please visit www.eurekatherapeutics.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
4 minutes ago
- Bloomberg
Cargill Pays Billionaire Owners a Record $1.5 Billion Dividend
Cargill Inc. paid a record dividend to the billionaire families who control the world's biggest agricultural commodities trader after profits surged 44% in its most recent financial year. The largest privately-held company in the US by revenue paid out almost $1.5 billion in the year ended May 31, according to the company's audited annual accounts seen by Bloomberg News. That's up almost 25% from a year earlier and eclipsed the previous record dividend in 2022, when Cargill made the most money in its 160-year history.
Yahoo
an hour ago
- Yahoo
Barrington Lifts PT on Orthofix Medical (OFIX) to $17 From $16, Keeps an Overweight Rating
Orthofix Medical Inc. (NASDAQ:OFIX) is one of the . Barrington analyst Michael Petusky raised the firm's price target on Orthofix Medical Inc. (NASDAQ:OFIX) to $17 from $16 on August 6, keeping an Outperform rating on the shares. A surgeon using a bone growth stimulator device in a modern operating theatre. The analyst told investors in a research note that Orthofix Medical Inc. (NASDAQ:OFIX) reported strong fiscal Q2 results and affirmed its 2025 outlook, supporting the optimistic rating. Orthofix Medical Inc. (NASDAQ:OFIX) announced its fiscal Q2 2025 results on August 5, reporting net sales of $203.1 million for the quarter, representing a 2% growth on a reported basis and 4% on a pro forma constant currency basis compared to Q2 2024. U.S. Spine Fixation underwent a net sales growth of 5% and procedure volume growth of 7% compared to the same quarter last year, while Bone Growth Therapies' net sales reached $62.6 million, representing growth of 6%. Orthofix Medical Inc. (NASDAQ:OFIX) provides medical devices and operates through the Global Spine and Global Extremities business segments. Its Global Spine reporting segment encompasses three primary product categories: Bone Growth Therapies, Spinal Implants, and Biologics. While we acknowledge the potential of OFIX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Business Wire
an hour ago
- Business Wire
CARMAT Provides an Update on the Ongoing Receivership Procedure
PARIS--(BUSINESS WIRE)--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the ' Company ' or ' CARMAT '), today provides an update on the ongoing receivership procedure and announces the suspension of trading in CARMAT shares, starting August 14, 2025, before stock market opening, ahead of the court hearing scheduled on August 19, 2025. Update on the ongoing receivership procedure Following a call for public tenders (buyers or investors) initiated as part of the receivership opened on July 1, 2025, the judiciary administrator had received, by the deadline of July 31, 2025, one takeover bid within the context of a sales plan (the 'Bid') 1. This Bid will be assessed by the Versailles Economic Court 2 (the "Court") at a hearing scheduled on August 19, 2025. The Company again draws attention to the fact that there is no guarantee at this stage that this Bid will be successful. The Company also reminds that even if the Bid is validated by the Court, the Company's shareholders and creditors may incur a significant loss of up to the total value of their investment or receivables. CARMAT is subject to a risk of liquidation, including in the short term. Suspension of CARMAT shares trading (ISIN code: FR0010907956, Ticker: ALCAR) Ahead of the court hearing scheduled on August 19, 2025, CARMAT has asked Euronext to suspend the trading of its shares starting on August 14, 2025, before the stock market opens. Another press release will be issued by the Company once the outcome of the court hearing is known. In any case, CARMAT endeavors to provide continuous support to patients who currently benefit from its Aeson® artificial heart. ●●● About CARMAT CARMAT is a French MedTech that designs, manufactures and markets the Aeson ® artificial heart. The Company's ambition is to make Aeson ® the first alternative to a heart transplant, and thus provide a therapeutic solution to people suffering from end-stage biventricular heart failure, who are facing a well-known shortfall in available human grafts. The world's first physiological artificial heart that is highly hemocompatible, pulsatile and self-regulated, Aeson ® could save, every year, the lives of thousands of patients waiting for a heart transplant. The device offers patients quality of life and mobility thanks to its ergonomic and portable external power supply system that is continuously connected to the implanted prosthesis. Aeson ® is commercially available as a bridge to transplant in the European Union and other countries that recognize CE marking. Aeson ® is also currently being assessed within the framework of an Early Feasibility Study (EFS) in the United States. Founded in 2008, CARMAT is based in the Paris region, with its head offices located in Vélizy-Villacoublay and its production site in Bois-d'Arcy. The Company can rely on the talent and expertise of a multidisciplinary team of circa 200 highly specialized people. CARMAT is listed on the Euronext Growth market in Paris (Ticker: ALCAR / ISIN code: FR0010907956). For more information, please go to and follow us on LinkedIn. Disclaimer This press release and the information it contains do not constitute an offer to sell or subscribe, nor a solicitation of an offer to buy or subscribe, for CARMAT shares in any country. This press release may contain forward-looking statements regarding the Company's objectives and outlook. These forward-looking statements are based on the current estimates and anticipations of the Company's management and are subject to risk factors and uncertainties, including those described in its Universal Registration Document filed with the French Financial Markets Authority (Autorité des marchés financiers) (the 'AMF') under number D.25-0345 (the ' 2024 Universal Registration Document '), available free of charge on the websites of CARMAT ( and the AMF ( Readers' attention is particularly drawn to the fact that the Company is currently placed in receivership (opened on July 1, 2025) and is facing a risk of liquidation including in the very short term. The Company is also exposed to other risks and uncertainties, such as its ability to implement its strategy, the pace of development of its production and sales, the progress and results of ongoing or planned clinical trials, technological developments, the competitive landscape, regulatory changes, industrial risks, and all risks related to the management of the Company's growth. Forward-looking statements mentioned in this press release may not be achieved due to these factors or other unknown risks and uncertainties, or risks that the Company does not currently consider to be material or specific. Aeson® is an active implantable medical device commercially available in the European Union and other countries recognising the CE mark. The Aeson® total artificial heart is intended to replace the ventricles of the native heart and is indicated as a bridge to transplant in patients with end-stage biventricular heart failure (Intermacs classes 1-4) who cannot benefit from maximal medical therapy or a left ventricular assist device (LVAD) and who are likely to benefit from a heart transplant within 180 days of implantation. The decision to implant and the surgical procedure must be carried out by healthcare professionals trained by the manufacturer. The documentation (clinician's manual, patient's manual and alarm booklet) must be read carefully to learn about the characteristics of Aeson® and the information required for patient selection and proper use (contraindications, precautions, side effects) of Aeson®. In the United States, Aeson® is currently only available as part of a feasibility clinical trial approved by the Food & Drug Administration (FDA). 1 Offre de reprise en plan de cession » (in French). 2 Tribunal des Activités Economiques de Versailles.
